Pancreatic ductal adenocarcinoma
Also known as: PDAC, Pancreatic adenocarcinoma, Ductal adenocarcinoma of the pancreas
Pancreatic ductal adenocarcinoma is an aggressive exocrine pancreatic malignancy. Clinical presentation may include abdominal or back pain, jaundice, weight loss, malabsorption, and diabetes. Care requires a specialist multidisciplinary team; surgery, systemic therapy, and supportive or palliative care depend on disease extent and patient priorities. While TCM diagnostic frameworks may provide an adjunctive structure for discussing symptoms, these assessments must not delay conventional oncological investigation or treatment. Cited research explores laboratory mechanisms involving ferroptosis, computational triptolide-associated prognostic models, and the tumour microenvironment (with one record lacking an abstract). No clinical evidence confirms that acupuncture or the specified herbal formulas improve survival, tumour response, or symptoms. Traditional pattern descriptions serve as references only and do not constitute cancer classifications or treatment recommendations.
Plain-English one-pager you can print or hand to a patient. Free, no sign-in needed.
Lifestyle & Diet
- •Consume small, frequent meals as tolerated and consult an oncology dietitian regarding protein and caloric intake; avoid restrictive dietary regimens.
- •Maintain gentle physical activity within individual fatigue thresholds, incorporating rest intervals and mobility assistance if postural instability occurs.
- •Maintain a systematic log of symptoms and pharmacology, documenting appetite, bowel function, pain intensity, nausea, and weekly body mass measurements.
- •Cessation of tobacco use is mandatory; consult the oncology team prior to the consumption of alcohol, nutritional supplements, or herbal pharmacopoeia.
Cautions & Contraindications
- •Defer needling with fever, suspected infection, clinically significant neutropenia or thrombocytopenia until the oncology team has assessed safety. The supplied abstracts do not provide needling thresholds or procedural safety guidance.
- •Avoid needling through tumour, infected or broken skin, unhealed surgical wounds, irradiated damaged tissue, vascular access devices or lymphoedematous areas. Anticoagulation, neuropathy and frailty require individual assessment.
- •Do not use triptolide or triptolide-associated products on the basis of the prognostic modelling study. Computational target predictions, docking and tissue expression do not establish therapeutic benefit, safe dosing or compatibility with oncology medicines.[]
- •Do not present herbal formulas or supplements as validated ferroptosis-inducing or macrophage-reprogramming cancer treatments. The supplied reviews describe research directions, not established clinical efficacy of these interventions.[,]
- •Do not start the listed formulas without full medicine reconciliation and oncology pharmacist review, particularly around surgery, chemotherapy, anticoagulation, pregnancy or impaired liver and kidney function. These are general precautions, not findings established by the supplied abstracts.
When to reassess or seek care again
Establish baseline pain and nausea scores on a 0–10 scale, intake, bowel symptoms, weight and functional tolerance. Review after 1–2 weeks of any agreed adjunctive care, earlier during active treatment or deterioration. Stop or modify interventions if adverse effects occur or there is no meaningful symptom improvement within 2–4 weeks. Escalate ongoing weight loss, declining intake or function, new jaundice or increasing rescue medicine use to the oncology team promptly; emergency findings require immediate assessment. Tumour response remains the responsibility of oncology, not TCM pattern reassessment.
Explore more diseases
Sources & Further Reading
Clinical guidance, red flags and safety notes on this page draw on the following current sources alongside the classical references above.
- Frontiers in cell and developmental biology · 2026
- Medical oncology (Northwood, London, England) · 2026
- Chinese herbal medicines · 2026
- Journal of physiology and biochemistry · 2026
Educational reference for licensed practitioners. Not a substitute for individual clinical assessment. Refer to conventional care for any red-flag or undiagnosed presentation.
